Clinical Trial Update: Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial update for Leuprolide Acetate 3.75 mg Depot Injection in advanced prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Leuprolide Acetate 3.75 mg Depot Injection (leuprolide acetate)

Snippet

Sponsor: Bharat Serums and Vaccines Limited | Conditions: Advanced Prostate Adenocarcinoma | Phase 3 | Status: COMPLETED